Joseph K. Belanoff
of and this for Thank year everyone, Korlym. Korlym number patients afternoon. XXXX Corcept. for receiving was brought a new of a thank you, you, record Each and XXXX prescribers great joining quarter successive Charlie, us
Our physicians before. treating rapidly previously was know assumed. hypercortisolism ever number They and than increasing more that than screening more of patients now many prevalent is are much
grow We syndrome continue are confident for to years. will our that business Cushing's
proprietary drug a On cortisol December application relacorilant. XX, for submitted modulator, our new we selective
results compelling long-term Phase studies. extension relacorilant II GRACE, from on is Our the based NDA GRADIENT, and
half Patients double-blind and III Phase received to relacorilant relacorilant weeks. In opportunity which enter phase, withdrawal parts. the and were hyperglycemia placebo or phase, hypertension, hypercortisolism given Our pivotal trial's to study XX GRACE continued the receive in XX of patients both XXX had the with for trial's patients for open-label either weeks. the half improvements met randomized X received prespecified who
measures. blood of that improved randomized of taking compared GRACE, other control. taking X.XX clinically taking retaining primary relacorilant means primary of which of weight phase pressure open-label In meaningful taking which important response An compared of Life and relacorilant cognition, withdrawal and maintain a in endpoint, those the hyperglycemia, statistically Patients GRACE X.XX. significant with odds hypertension, clinical in to its p-value improvements ratio circumference, mass, the weight, Quality patients endpoint ratio, lean those exhibited patients the likely placebo. muscle placebo, to Cushing’s score relacorilant was odds The blood pressure of study's were X.XX was met more their to Xx phase
significant study, who who relacorilant in generated In or placebo continued the range addition, of experienced first received continued extension completed time. in hypercortisolism patients eligible long-term and received relacorilant of a phase to and worsening receive in the the to Phase arm the other were where study and in withdrawal for open-label of the or studies Patients patients randomized symptoms. who phase the signs relacorilant, signs placebo improvements broad of GRADIENT they increased symptoms maintained to while study, take the these those our of enter the the II for GRACE of GRADIENT,
cardiometabolic study taken This meaningful Patients years. improvements. exhibited to XXX X group has in for the up extension durable additional clinically have now relacorilant patients and of
these sorry, For diastolic of study instance, at p-value the study. of I'm millimeters p-value in of study, to the X.XXX further exhibited blood entered improvements already of were a experienced pressure in II blood pressure mercury, and GRACE mercury, a compared they time the of Phase of to extension XX parent Again, the for GRADIENT instance, of at study. XX XX X.XXX, millimeters week the -- systolic X.X improvements they reduction in at a or month please those their their of measurements the remember, addition
study, is complete evident in of safety, and discuss in GRACE which GRADIENT will as a extension then the the course clinical study. the they patients I one participate II clearly efficacy follows enter Phase long-term moment, study, when that Relacorilant's or
improvements whose randomized improvement therapy, improve by treatment in the placebo, maintained patients of in rapid by at relacorilant extension relacorilant placebo restarted. followed the phase study. the interrupted, rapid start is improvement at or of a for Patients which continues group, therapy, instance, is exhibit to As the being switched when to assigned when deterioration resumption start relacorilant exhibit GRACE then withdrawal to of relacorilant
has consistent its back and most Just and as The all efficacy mild of safety. Relacorilant tolerated to fatigue. edema, pain in in well studies. nausea, have its adverse events moderate important extremities as the been relacorilant's common been is with hypercortisolism the are cortisol that of at withdrawal surgery reduction to These in following experience with symptoms removes due cortisol-secreting a rapid ACTH an activity, tumor therapy. the that or whether medical their start cortisol or patients
serious As These for of of them. expected, prolongation. or bleeding, no of can X consequences. there instances the events cases more hypertrophy cause have insufficiency no of currently can of or relacorilant-induced hypokalemia, available instances no and Each Cushing's patients endometrial been drug-induced QT vaginal with syndrome have medications health adverse adrenal
large including In X.XX Mounjaro. awareness were hypercortisolism completed The received received already treatments and of The compared key who to especially prevalence a AXc, study CATALYST December, of far CATALYST striking, either patients X phase treatment exhibited in magnitude striking. in in were placebo. p-value decrease a who of work hypercortisolism. Patients X.XX% reduction, Korlym at with as in is of treatment receiving double-blind, physician a hemoglobin XXX type study difficult-to-control receive identified placebo, in that patients were and understanding than phase seen showed available, a that As placebo-controlled to given we our than higher these Ozempic advance or of a results has relacorilant, arm reduction we X continue to best patients control, diabetes less Korlym X.XXXX. a increasing assumed. phase, randomized hypercortisolism, first patients rate The having in the which the we was CATALYST's measure diabetes glucose X
X to patients addition have hypertension, diabetes. In establish finding common group hypercortisolism more to Later cardiovascular more hypertension. disease or substantial is patients to the that in study our in prevalence which in of CATALYST taking than Another who have hypercortisolism of in their with manage medications patients we is were CATALYST even resistant help X/X a start more found will this will MOMENTUM, study, newest hypercortisolism. quarter, the
awareness the this physician of We the with will are struggle impact combined and improve devastating of a of of lives disease. hypercortisolism, with relacorilant, patients confident advancement and who therapy, understanding that effective safe the increased
are already it. We seeing
plays for role. cancer we studying as a know, you treatment also As a of where are types cortisol relacorilant
soon either data to probably most pivotal nab-paclitaxel or plus We ovarian disease, effective women platinum-resistant with been women prescribed a our currently chemotherapy randomized study. on XXX ROSELLA study, nab-paclitaxel, relacorilant. In cancer platinum-resistant one-to-one the have receive to expect from this with basis
patients, treatment. For of nab-paclitaxel the has chemotherapy these or any much many of earlier course in become less than useful
trial. also that group patients of is the relacorilant day they to and the nab-paclitaxel nab-paclitaxel nab-paclitaxel, of were a tumors the of received will the study expectation resensitize compared activity. cortisol intermittent study, the relacorilant exhibited comparator II who statistically intermittently, day that relacorilant who to design after survival in Our the women who relacorilant effects start in tracks compared the XX% In longer in significant arm. the XX% duration the monotherapy. received nab-paclitaxel improvement effects successful took after progression-free years day who than only anti-apoptotic and Phase before, of took ovarian those blunting Women to controlled design the of our group alone. response lived alive received ROSELLA's X by of
who experienced no relacorilant to received side women additional those the Importantly, plus monotherapy. effect nab-paclitaxel nab-paclitaxel received who burden compared
replicate to these results. We expect relacorilant
progression-free is anticipate ROSELLA We quarter. the results having in of survival this complete. by Enrollment end
ENGOT for Oncology ROSELLA conducting European Group group Europe in United Gynecologic Trial their Trials the European and with the appreciate the GOG ] from leading collaboration States and Oncological in Gynaecological support. [ are enthusiasm or Gynecologic We of or Network in clinicians Oncology deeply Network and (sic)
that so outcome, treatment stand-alone and us glucocorticoid Positive In also a solid established relacorilant tumors a earlier results the to conclusion we swiftly the of who from division as express a move relacorilant benefit to we it. bring cancer anticipation can oncology after stages receptor. women of have to of explore ovarian the successful other ROSELLA can for will prompt
Cortisol a treated evaluating reason tumor with growth. stimulation, to patients activity exploring chemotherapy, androgen stimulate with androgen use prescribed disease. widely is to a to to enzalutamide androgen addition resurgent we experience cortisol antagonist why are resensitize cortisol's in deprivation Deprived with their switch prostate potential cancer potential stimulation its receptor to of eventually therapy. tumors combination In major
this route. modulation escape hypothesize Leading academic can researchers clinicians tumor that and cortisol block
had Our Chicago patients a enrolling University of Phase enzalutamide patients in collaborators prostatectomy. with have randomized II prostate currently placebo-controlled relacorilant initial an are of plus at before cancer trial these early-stage the
of cancer receptor role modulator cortisol system, immunotherapy. to cortisol in blunt combination enhance such may therapies cortisol stimulate response. intended their the an may checkpoint Because possible effectiveness. effectiveness of the a is as Adding suppresses to immune immunotherapies Another inhibitors immune it with antagonist
we're Ib trial cancer, Phase types of deciding in compounds tumor our other with in and our the stages in how immunotherapies adrenal Following earlier to investigate cancer. best advanced of combination utility
ALS, commonly is on compelling Based blood-brain disorders. improved used of reduced proprietary of a compounds, performance neurologic Functional model, candidate conducted the that dazucorilant for study's dazucorilant, crosses a who neuroinflammation data mouse double-blind, in One did Scale, atrophy endpoint. primary our and not the show trial of Phase barrier Rating randomized, dire readily in XXX-patient II the we the dazucorilant Unfortunately, a muscular improvement showing in disease. patients treatment and motor placebo-controlled received ALS in
the XX-patient statistically of patient the occurred However, milligrams we survival at p-value received improvement occurred study. in dazucorilant, ongoing, a patients expect is study second XX quarter. did deaths a No week who XXX deaths early observe in of X grid, while in significant receive placebo extension and X XX X.XX. in of overall to long-term the survival we results year The the open-label
the a treatment. serious of both United initial alone. and modulation States progression of cortisol in a may as Cortisol afflicts steatohepatitis, that disease, activity the dysfunction-associated serve disorder patients is the millions and development plays role metabolic a MASH, in liver
proprietary our liver. very of in activity potent the molecules, has One miricorilant,
of experienced just enzymes, Phase metabolic and tolerated, serum compound XX% in and of for a liver arise fat orally milligrams received Ib a of fibrosis well that in lipid for which Our patients who in GI and reduction was found improvements The as commonly and insulin weeks none liver side also such effects dose-finding MASH. twice XX treated the week miricorilant triglycerides patients key LDL. XXX being very resistance, measures with study markers
XXX reduction In endpoints. either is MONARCH resolution double-blind, for encouraging MONARCH or study randomized, of are weeks. fat placebo IIb as biopsy-confirmed milligrams to X our cohorts. to liver Our the biopsy-confirmed MASH randomized on The with key weekly Phase is MASH primary fibrosis XX Ib with first, improvement miricorilant this Phase and aims XXX patients cohort enrolling endpoint in secondary receive results. placebo-controlled X:X expand twice for
for fat. the Patients for MASH. The liver the will planned XX of by second receive in XXX presumed a cohort XX in has followed with this enrollment XXX for be either weekly also whole reduction endpoint X:X to In placebo or cohort X miricorilant of weeks, twice cohort, this weeks patients is XX milligrams twice milligrams miricorilant primary randomized weekly weeks.
As I Corcept. year for earlier, a great XXXX said was
for years of hypercortisolism even Physicians expect becoming clinical are consequences. greater come. and We aware success increasingly to its
of further and advance demonstrating have highly understanding that new cortisol patients that that a for translate modulation is to clearly provide results We receiving CATALYST and evidence than prescribers to treatment The record more cortisol therapy. seen modulator the assumed long is much string effective. a hypercortisolism previously field by with potent common quarters
safety Relacorilant's results strong successful relacorilant Phase profile from extension hypercortisolism. the for NDA long-term standard and with hypercortisolism. The efficacy support GRADIENT, II and it in powerful provide of become studies positions to for care our positive new GRACE, patients
programs Meanwhile, our development continue advance. to
study in ROSELLA We in expect ovarian our from a just weeks. few cancer results pivotal
quarter. plan initiate ongoing, and are this cancer our prostate Our study studies and ALS we MOMENTUM MASH to
but on with a very active distinctive we proprietary selective should and research many We don't time portfolio, much the calls know also modulators cortisol discussing broad clinical that spend topic, you these have attributes. potential
comprehensively are will and evaluating attributes their therapeutic these advance We and most clinic. compounds the applications to promising the
excess The often problems cortisol negative have effects caused on profoundly patients. by activity
effective proceed new, to Operator, more safer to them. now let's We to treatments and are dedicated questions. finding help
